This study was designed to specifically identify therapeutic compounds that can effectively prevent CCM lesion formation and progression through inhibition of the MEKK3-KLF-ADAMTS signaling axis. The strategy used an FDA-approved kinase screen to identify compounds that inhibited KLF2/4 gene expression levels in CCM1/2-deficient endothelial cells. Ponatinib was found to be the most promising candidate following in vitro studies and testing in in vivo mouse models of CCM lesion development. The endothelial-specific Ccm1 or Ccm2 knockout (Ccm1iECKO or Ccm2iECKO) mice on C57Bl/6 background were treated with sham or ponatinib. Animals were randomly assigned to treatment groups from litters with at least four pups. Only data from animal studies with the appropriate littermate controls (Cre-negative controls, Ccm1iECKO or Ccm2iECKO pups treated with sham, and Ccm1iECKO or Ccm2iECKO treated with ponatinib) were included in the analysis. Therapeutic potential of ponatinib was examined by micro-CT for reductions in lesion number, size, and volume. Changes in gene expression were measured by qPCR. Restoration of misaligned endothelial lining was observed by scanning electron microscopy.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.